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Prolonged Prevention of Acute Graft-Versus-Host Disease After 
Allogeneic Bone Marrow Transplantation by Donor Pretreatment 
Using FK 506 
M.H. Cooper, P.M. Markus, X. Cai, T.E. Starzl, and J.J. Fung 
ACUTE graft-versus-host disease (GVHD) is a sys-
temic manifestation of activation of normal allodis-
parate transplanted lymphoid cells to recipient epithelial 
target organs. In clinical bone marrow transplantation 
(BMT) between HLA identical siblings, acute GVHD 
occurs in up to 50% of cases, 1 many times during the early 
posttransplant period. It has recently been shown that FK 
506 is superior to cyclosporine (Cy A) for the prevention of 
lethal acute GVHD after allogeneic bone marrow trans-
plantation in the rat. 2 It is known that FK 506 compared to 
Cy A in vitro has a higher potency with regard to its effects 
on the early events of T-cell activation. particularly if FK 
506 is present at or before the time of antigenic stimulation. 
We have examined whether a single treatment of the 
allogeneic donor, either alone, in combination with contin-
uous recipient prophylactic therapy, or with discontinuous 
recipient therapy, could significantly prolong the GVHD-
free interval and subsequent overall survival after fully 
allogeneic bone marrow transplantation in our previously 
described animal model. 2 
MATERIALS AND METHODS 
Animals 
Male Lewis (RT-Il) and ACI (RT-la) rats (Harlan Sprague Daw-
ley, Indianapolis, Ind), aged 7 to 9 weeks. were used in all 
experiments. Animals were maintained in a laminar flow caging 
system (Thorens Caging Systems) and given acidified water as 
described previously. 2 
BMT and Assessment of GVHD 
BMT was performed according to a protocol previously described 
at our institution.2 Briefly, bone marrow and spleen cells were 
prepared as single-cell suspensions. Sixty million ACI bone mar-
row and 30 million spleen cells were injected via the penile vein 
into lethally irradiated (1000 rad) Lewis recipients. All animals 
received antibiotics in the immediate posttransplant period. All 
animals were observed daily for evidence of GYHD. Clinical and 
histological criteria (as assessed by weekly ear biopsies) used for 
the diagnosis of GYHD. have been described in a previous study 
from our institution.2 
Immunosuppression 
FK 506 was a gift from Fujisawa Pharmaceutical Co (Osaka, 
Japan). The powder with carrier solvent was diluted in normal 
saline for 1M injections. FK 506 was given once a day. unless 
otherwise specified. 
Study Design and Statistical Analysis 
The allocation of groups is shown in Table I. Groups of animals 
received an allogeneic bone marrow,grllfi from donor animals that 
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Table 1. Group Assignments ShOWing Donor and 
Recipient Treatments 
Donor Recipient 
Treatment Treatment 
Group n (Days) (Days) 
A 10 0 H 
B 8 0 3-8 
C 8 0 
D 10 H 
E 8 3-8 
F 8 0 0 
All FK 506 doses were 1 mglkg per day 1M. 
had either received either one dose of FK 506 or no drug. The 
respective recipients received either no additional therapy, a 
course of FK 506 starting on day 0, or a course of FK 506 starting 
on day 3. The GYHD-free interval and survival were compared 
between groups. Statistical analysis was performed using Stu-
dent's t test. P < .05 was considered significant. 
RESULTS 
The mean GVHD-free interval and survival are shown in 
Table 2. The addition of one dose of FK 506 (I mg/kg) 
significantly prolonged the mean GVHD-free survival and 
survival when compared to no donor pretreatment (P = 
.01). When donor pretreatment was added to a 0- to 6-day 
course of FK 506 (l mg/kg) given to the recipient, and 
compared to a recipient 0- to 6-day course of FK 506 alone. 
the GVHD-free interval was extended from 42 to 60 days 
(P < .(01). When donor pretreatment was combined with 
a 3- to 8-day course of FK 506 given to the recipient, the 
GYHD-free interval was again prolonged in comparison to 
a recipient course alone, although by a smaller degree than 
when the recipients had received a 0- to 6-day course of 
therapy. When the recipients received no therapy, the 
addition of one dose of FK 506 given to the donor was, by 
itself, sufficient to prolong the GVHD-free interval. The 
differences in mean GVHD-free intervals between these 
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PREVENTION OF ACUTE GVHD AFTER BMT 
Table 2. Mean Time to GVHD and Mean Survival 
Mean Time to GVHD Mean Survival 
Group (Days Post-BMT) (Days Post-BMT) 
A 42.0::!: 3.1 45.0::!: 4.6 
B 45.0 ± 4.6 48.0 ± 5.1 
C 12.7 ± 1.3 18.8 :t 0.87 
0 6O.0::!: 5.9 64.0::!: 6.13 
E 52.0::!: 4.8 59.0:t 6.2 
F 10.O::!: 1.1 15.0::!: 1.7 
All values are means:!: SEM. 
groups were reflected in the differences of mean survival 
times (Table 2). 
DISCUSSION 
In this study, we have shown that the addition of one dose 
of the immunosuppressant, FK 506, to an allogeneic bone 
marrow donor can significantly prolong the mean GVHD-
free interval after allogeneic BMT. This donor pretreat-
ment therapy gives better results when combined with a 
recipient course of FK 506 from days 0 to 6 rather than 3 
to 8, and it may be that continuous therapy is more 
beneficial than fragmented prophylaxis. The most likely 
explanations for these observations are drug carry-over 
effects or residual inhibitory affects on T cells. Drug 
carry-over effects are the most likely explanation, since it 
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became known that FK 506 is difficult to remove from in 
vitro systems.3 The alternative possibility is a direct effect 
on the donor cells prior to BMT. Perhaps it is possible that 
this question could be addressed by measuring donor 
blood levels of FK 506 and waiting until these return to 
zero. This would then eliminate carry-over effects and 
allow assessment of whether pretreatment of the cells 
gives additional immunosuppressive activity. There is also 
the prospect of recipient pretreatment for solid organ 
allografting, and whether this is valuable in reducing 
incidence or severity of allograft rejection. FK 506 has 
been shown to be effective in delaying the onset of 
rejection in the heterotopic heart allograft model in the 
rat. 4 Therefore, we conclude that pretreatment of an 
allogeneic donor prior to BMT with FK 506 can prolong 
the GVHD-free interval and survival, particularly when 
this treatment is combined with continuous recipient ther-
apy. 
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